Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 Aug;97(2):260–265. doi: 10.1111/j.1365-2249.1994.tb06078.x

Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection.

A Carr 1, E Vasak 1, V Munro 1, R Penny 1, D A Cooper 1
PMCID: PMC1534695  PMID: 8050175

Abstract

The pathogenesis of drug hypersensitivity in patients with HIV infection is unknown. To study further the nature of hypersensitivity, the histopathological features of morbilliform drug hypersensitivity reactions were examined in a group of HIV-infected patients. Skin sections from 23 HIV-infected subjects with morbilliform drug hypersensitivity reactions were examined by light microscopy, direct immunofluorescence and immunohistochemistry, to determine the nature of the inflammatory infiltrate and the role of immunoglobulin, complement and cytokines. The principal light microscopic findings were spongiosis, hydropic generation of the basal layer, civatte bodies, an epidermal lymphocytic infiltrate (48%), and a perivascular dermal infiltrate of lymphocytes (87%) and macrophages (52%). Two patients had findings consistent with toxic epidermal necrolysis. Immunohistochemistry demonstrated that the lymphocytic infiltrate consisted of CD8+, HLA-DR+ T lymphocytes (some of which also stained for CD38), a marked depletion of epidermal Langerhans cells (90%), and strong cytoplasmic staining of keratinocytes for IL-6 (60%), IL-1 beta (50%), tumour necrosis factor-alpha (TNF-alpha) (45%) and to a lesser degree, interferon-gamma (IFN-gamma) (35%). Immunofluorescence did not demonstrate any significant deposition of immunoglobulin or complement. The histological findings were independent of the responsible drug, the duration of either therapy or the rash, and of peripheral blood CD4+ and CD8+ cell counts. These findings suggest that activated CD8+ lymphocytes and perhaps epidermal production of cytokines are involved in the pathogenesis of cutaneous drug hypersensitivity in HIV-infected patients. The common histological features, regardless of the causative drug, suggest a common pathogenesis.

Full text

PDF
260

Images in this article

262Fig. 1
on p.262
263Fig. 2
on p.263

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. A coordinated approach to children's health in India: progress report after five years (1975-1980). Lancet. 1983 Jan 15;1(8316):109–111. [PubMed] [Google Scholar]
  2. Alpers C. E., Hopper J., Jr, Bernstein M. J., Biava C. G. Late development of systemic lupus erythematosus in patients with glomerular "fingerprint" deposits. Ann Intern Med. 1984 Jan;100(1):66–68. doi: 10.7326/0003-4819-100-1-66. [DOI] [PubMed] [Google Scholar]
  3. Carr A., Cooper D. A., Penny R. Allergic manifestations of human immunodeficiency virus (HIV) infection. J Clin Immunol. 1991 Mar;11(2):55–64. doi: 10.1007/BF00917741. [DOI] [PubMed] [Google Scholar]
  4. Carr A., Gross A. S., Hoskins J. M., Penny R., Cooper D. A. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS. 1994 Mar;8(3):333–337. doi: 10.1097/00002030-199403000-00006. [DOI] [PubMed] [Google Scholar]
  5. Carr A., Swanson C., Penny R., Cooper D. A. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis. 1993 Jan;167(1):180–185. doi: 10.1093/infdis/167.1.180. [DOI] [PubMed] [Google Scholar]
  6. Carr A., Tindall B., Penny R., Cooper D. A. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol. 1993 Oct;94(1):21–25. doi: 10.1111/j.1365-2249.1993.tb05971.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Coopman S. A., Johnson R. A., Platt R., Stern R. S. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993 Jun 10;328(23):1670–1674. doi: 10.1056/NEJM199306103282304. [DOI] [PubMed] [Google Scholar]
  8. Dreno B., Milpied B., Dutartre H., Litoux P. Epidermal interleukin 1 in normal skin of patients with HIV infection. Br J Dermatol. 1990 Oct;123(4):487–492. doi: 10.1111/j.1365-2133.1990.tb01454.x. [DOI] [PubMed] [Google Scholar]
  9. Dréno B., Milpied B., Bignon J. D., Stalder J. F., Litoux P. Prognostic value of Langerhans cells in the epidermis of HIV patients. Br J Dermatol. 1988 Apr;118(4):481–486. doi: 10.1111/j.1365-2133.1988.tb02456.x. [DOI] [PubMed] [Google Scholar]
  10. Fauci A. S. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 1988 Feb 5;239(4840):617–622. doi: 10.1126/science.3277274. [DOI] [PubMed] [Google Scholar]
  11. Gordin F. M., Simon G. L., Wofsy C. B., Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984 Apr;100(4):495–499. doi: 10.7326/0003-4819-100-4-495. [DOI] [PubMed] [Google Scholar]
  12. Matis W. L., Triana A., Shapiro R., Eldred L., Polk B. F., Hood A. F. Dermatologic findings associated with human immunodeficiency virus infection. J Am Acad Dermatol. 1987 Nov;17(5 Pt 1):746–751. doi: 10.1016/s0190-9622(87)70257-6. [DOI] [PubMed] [Google Scholar]
  13. Mitsuyasu R., Groopman J., Volberding P. Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma. N Engl J Med. 1983 Jun 23;308(25):1535–1536. doi: 10.1056/NEJM198306233082512. [DOI] [PubMed] [Google Scholar]
  14. Rieder M. J., Uetrecht J., Shear N. H., Cannon M., Miller M., Spielberg S. P. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med. 1989 Feb 15;110(4):286–289. doi: 10.7326/0003-4819-110-4-286. [DOI] [PubMed] [Google Scholar]
  15. Sattler F. R., Cowan R., Nielsen D. M., Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med. 1988 Aug 15;109(4):280–287. doi: 10.7326/0003-4819-109-4-280. [DOI] [PubMed] [Google Scholar]
  16. Wharton J. M., Coleman D. L., Wofsy C. B., Luce J. M., Blumenfeld W., Hadley W. K., Ingram-Drake L., Volberding P. A., Hopewell P. C. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med. 1986 Jul;105(1):37–44. doi: 10.7326/0003-4819-105-1-37. [DOI] [PubMed] [Google Scholar]
  17. Zola H., Mantzioris B. X., Webster J., Kette F. E. Circulating human T and B lymphocytes express the p55 interleukin-2 receptor molecule (TAC, CD25). Immunol Cell Biol. 1989 Aug;67(Pt 4):233–237. doi: 10.1038/icb.1989.35. [DOI] [PubMed] [Google Scholar]
  18. Zola H., Neoh S. H., Mantzioris B. X., Webster J., Loughnan M. S. Detection by immunofluorescence of surface molecules present in low copy numbers. High sensitivity staining and calibration of flow cytometer. J Immunol Methods. 1990 Dec 31;135(1-2):247–255. doi: 10.1016/0022-1759(90)90278-4. [DOI] [PubMed] [Google Scholar]
  19. van der Ven A. J., Koopmans P. P., Vree T. B., van der Meer J. W. Adverse reactions to co-trimoxazole in HIV infection. Lancet. 1991 Aug 17;338(8764):431–433. doi: 10.1016/0140-6736(91)91046-w. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES